| 纯度 | >90%SDS-PAGE. |
| 种属 | Escherichia coli |
| 靶点 | idnk |
| Uniprot No | P39208 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-187aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMAGESFI LMGVSGSGKT LIGSKVAALL SAKFIDGDDL HPAKNIDKMS QGIPLSDEDR LPWLERLNDA SYSLYKKNET GFIVCSSLKK QYRDILRKGS PHVHFLWLDG DYETILARMQ RRAGHFMPVA LLKSQFEALE RPQADEQDIV RIDINHDIAN VTEQCRQAVL AIRQNRICAK EGSASDQRCE |
| 预测分子量 | 23 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IDNK(异柠檬酸脱氢酶激酶/磷酸酶)重组蛋白研究的示例性参考文献(注：文献为虚拟示例，实际研究中请核实具体论文)：
1. **"Functional characterization of recombinant IDNK from *Escherichia coli*: Role in metabolic regulation"**
- **作者**: Smith J, et al.
- **摘要**: 本研究成功在大肠杆菌中表达并纯化IDNK重组蛋白，证实其具有双重酶活性(激酶/磷酸酶)，并通过体外实验揭示其在三羧酸循环中对异柠檬酸脱氢酶的动态调控机制。
2. **"Crystal structure and catalytic mechanism of IDNK from *Mycobacterium tuberculosis*"**
- **作者**: Li X, Wang Y.
- **摘要**: 通过X射线晶体学解析结核分枝杆菌IDNK重组蛋白的三维结构，结合突变体分析，阐明了其底物结合位点及催化残基，为开发新型抗菌药物提供结构基础。
3. **"High-yield production of IDNK recombinant protein in *Pichia pastoris* and its industrial applications"**
- **作者**: Chen L, et al.
- **摘要**: 报道毕赤酵母系统中IDNK重组蛋白的高效分泌表达策略，优化发酵条件后酶活提升5倍，并验证其在生物催化合成α-酮戊二酸中的潜在应用价值。
4. **"IDNK deficiency alters cellular metabolism: Insights from recombinant protein rescue experiments"**
- **作者**: Gonzalez R, et al.
- **摘要**: 利用IDNK重组蛋白回补实验，证明IDNK缺失导致细胞线粒体氧化应激和ATP合成异常，提示其在代谢疾病中的潜在作用靶点。
**提示**：以上文献为生成示例，实际研究中建议通过PubMed、Web of Science等平台检索最新论文，并核实IDNK的具体研究背景(不同物种或疾病模型中的功能可能存在差异)。
IDNK (International Designation of Novel Kinase) recombinant protein is a synthetically engineered biomolecule designed to mimic or modify specific kinase functions in cellular signaling pathways. Kinases are enzymes pivotal in regulating processes like cell growth, metabolism, and apoptosis, making them critical targets for therapeutic and research applications. The development of IDNK recombinant protein emerged from the need to study kinase-related mechanisms with higher precision and scalability than traditional methods allow. By leveraging recombinant DNA technology, IDNK is produced in host systems (e.g., *E. coli*, yeast, or mammalian cells*), enabling large-scale, reproducible synthesis of kinase domains or full-length proteins with tailored modifications.
This protein’s design often incorporates tags (e.g., His-tags, GST) to facilitate purification and detection, ensuring high purity and activity. Researchers utilize IDNK recombinant proteins in drug discovery, particularly for high-throughput screening of kinase inhibitors, which are vital in treating cancers, autoimmune diseases, and neurodegenerative disorders. Its recombinant nature allows customization—mutations can be introduced to study gain- or loss-of-function phenotypes or to stabilize active/inactive conformations for structural studies (e.g., X-ray crystallography).
The background of IDNK also reflects advancements in biopharmaceuticals, where recombinant kinases serve as tools to validate targets or as reference standards in diagnostic assays. Challenges in its development include maintaining proper post-translational modifications (e.g., phosphorylation) in prokaryotic hosts, often necessitating eukaryotic expression systems. Overall, IDNK recombinant protein exemplifies the intersection of molecular biology and translational research, offering a versatile platform to dissect kinase biology and accelerate therapeutic innovation.
×
